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Susceptibility of Streptococcus agalactiae
isolates from blood and urine to 18 widely
used and recently marketed antibiotics
In a recent article in Clinical Microbiology and
Infection, we reported the susceptibility of strains
of Streptococcus agalactiae collected in 1997–99 to
macrolides and lincosamides [1]. Subsequently,
we have studied the susceptibilities of 145 strains
of S. agalactiae collected in 1998–2002 to 18
widely used and recently marketed antibiotics.
Most (115) of the strains were from urine
samples in 2002 and were associated with
asymptomatic bacteriuria in pregnant women
or urinary tract infections in the non-gestating
population, while the remaining 30 strains were
from bacteraemias diagnosed in 1998–2002. The
MIC of each antibiotic was determined by the
agar dilution method, as described in our previ-
ous study [1]. The results obtained are shown in
Table 1.
As in most published studies from other
countries [2–4], the S. agalactiae isolates from
Madrid were still susceptible to the b-lactam
antibiotics tested. However, resistance to peni-
cillin has been described elsewhere, albeit at a
low frequency [5]. In contrast, a gradual increase
in resistance to macrolides and lincosamides has
been described in recent years [2–5], and resist-
ance levels approaching 20% were found in the
present study. These values were slightly higher
than those described previously in Spain. Thus,
in 1997–99, there were resistance levels in
Madrid of 16% for erythromycin and azithro-
mycin, and 13% for miocamycin and clindamy-
cin [1]. Similarly, Betriu et al. [6] described a
significant increase in resistance to macrolides
and lincosamides over the period 1993–2001,
with resistance levels nearing 17% for erythro-
mycin and 12% for clindamycin. The high
resistance level (83.5%) observed for tetracycline
was similar to that reported in Canada and
France [2,7], but was lower than the 26%
resistance level reported in Japan [8]. All the
S. agalactiae strains studied were susceptible to the
new antibiotics tested, with MIC90s of 0.12 mg ⁄L
for moxifloxacin, 0.06 mg ⁄L for telithromycin,
and 1 mg ⁄L for linezolid.
In conclusion, S. agalactiae isolates from
Madrid still appear to be susceptible to the
b-lactams used in the treatment of infections
caused by this species. However, levels of resist-
ance to macrolides and lincosamides are now
significant, and this fact must be considered by
the physician when prescribing empirical treat-
ment, and also by the microbiologist when
testing in-vitro susceptibilities. The recently mar-
keted antibiotics examined in the present study
Table 1. In-vitro susceptibility to 18
antibiotics of 145 Streptococcus aga-
lactiae strains isolated from blood
and urine
Antibiotic
MIC (mg/L)
% susceptibility BreakpointRange MIC50 MIC90
Penicillin G £ 0.3–0.12 0.06 0.12 100 £ 0.12a
Ampicillin 0.06–0.12 0.12 0.12 100 £ 0.25a
Cefotaxime £ 0.03–0.12 0.06 0.12 100 £ 0.5a
Azithromycin £ 0.06– > 16 £ 0.06 > 16 78 £ 0.5a
Erythromycin £ 0.06– > 16 £ 0.06 > 16 78 £ 0.25a
Miocamycin £ 0.25– > 16 0.5 > 16 80 £ 1b
Clindamycin £ 0.06– > 16 £ 0.06 > 16 80 £ 0.25a
Vancomycin £ 0.5 £ 0.5 £ 0.5 100 £ 1a
Gentamicin 8–32 16 32 – NA
Tetracycline £ 0.5– > 16 > 16 > 16 16.5 £ 2a
Rifampicin £ 0.12–1 £ 0.12 0.5 100 £1c
Fosfomycin 32 to > 64 64 > 64 94 £ 64d
Nitrofurantoin £ 8– > 64 £ 8 16 96 £ 32d
Ciprofloxacin 0.25–2 0.5 1 – NA
Moxifloxacin £ 0.03–0.25 0.12 0.12 100 £ 1c
Levofloxacin 0.5–2 0.5 1 100 £ 2a
Linezolid £ 0.5–2 1 1 100 £2a
Telithromycin £ 0.03–1 £ 0.03 0.06 – NA
NA, not available.
aNational Committee for Clinical Laboratory Standards (NCCLS) breakpoint for Streptococcus spp. other than
S. pneumoniae [9].
bSociete´ Franc¸aise de Microbiologie [10].
cNCCLS breakpoint for S. pneumoniae [9].
dNCCLS breakpoint for Enterococcus spp. [9].
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currently show good in-vitro activity against
S. agalactiae.
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